Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) - Trial NCT05536349
Access comprehensive clinical trial information for NCT05536349 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Leukemia. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 2
Feb 28, 2023
Apr 25, 2025
Primary Outcome
The severity of the adverse events (AEs) will be graded according to the U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.
Summary
To learn if the combination of pirtobrutinib (also called LOXO-305), venetoclax, and
 obinutuzumab is safe and effective when given to patients with chronic lymphocytic leukemia
 (CLL) or Richter transformation (RT) who have not previously received treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05536349
Non-Device Trial